Precision Neuroscience designs the Layer 7 Cortical Interface, which features 1,024 tiny electrodes spanning an area of one square centimeter. The company embedded the electrodes in a flexible film that conforms to the brain surface. The film comes in at one-fifth the thickness of a human hair. Precision Neuroscience designed it for implantation and removal by neurosurgeons without damaging brain tissue.
The company says it expects its brain implant to enable people with severe neurological conditions, like speech deficits and paralysis, to regain independence, communicate with loved ones and rejoin the workforce. Its BCI picked up an FDA breakthrough device designation last fall as in-human trials progress. With Precision, Otis’ responsibilities include leading BCI development.
Otis joins the company as an expert in chip design for low-power electronics. He co-founded Verily, the healthcare and life sciences company within Google/Alphabet. There, he served as chief technical officer and fellow from 2015 through 2022. He oversaw a large, multidisciplinary team in the end-to-end development of new medical technology.
At Verily, Otis’ leadership contributed to significant contributions in the healthcare and pharmaceutical space. His team helped develop the Dexcom G7 CGM and partnered with Novartis/Alcon on smart optical devices, among other ventures.
“After Verily, I spent a year and a half exploring opportunities,” Otis said. “After researching many different techniques to tackle brain–computer interfaces, I became convinced that Precision’s approach of using high-resolution surface electrodes is the right one to bring a powerful product to market. I’m excited to be part of the team that is going to build and scale the first mass-produced version of this technology.”
